Evidence map›Paper›PMID 33294858›Full record

ArticleCell reports. Medicine2020

A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury.

Maria Kost-Alimova, Eriene-Heidi Sidhom, Abhigyan Satyam, Brian T Chamberlain, Moran Dvela-Levitt, Michelle Melanson, Seth L Alper, Jean Santos, Juan Gutierrez, Ayshwarya Subramanian and 26 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 4 institutions in 2 countries.

Maria Kost-AlimovaThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Eriene-Heidi SidhomThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Abhigyan SatyamBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Brian T ChamberlainThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Moran Dvela-LevittThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Michelle MelansonThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Seth L AlperThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Jean SantosThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Juan GutierrezThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Ayshwarya SubramanianThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Patrick J ByrneThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Elizabeth GrinkevichThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Estefanía Reyes-BricioThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Choah KimThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Abbe R ClarkThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Andrew J B WattsThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Rebecca ThompsonThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Jamie MarshallThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Juan Lorenzo PabloThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Juliana CoraorThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Julie RoignotThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Katherine A VernonThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Keith KellerThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Alissa CampbellThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Maheswarareddy EmaniThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Matthew RacetteThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Silvana Bazua-ValentiThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Valeria PadovanoThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Astrid WeinsBrigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Stephen P McAdooDepartment of Immunology and Inflammation, Imperial College, Hammersmith Hospital, London, UK.
Frederick W K TamDepartment of Immunology and Inflammation, Imperial College, Hammersmith Hospital, London, UK.
Luciene RoncoThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Florence WagnerThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
George C TsokosBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Jillian L ShawThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Anna GrekaThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Broad Institute · USBeth Israel Deaconess Medical Center · USHammersmith Hospital · GBBrigham and Women's Hospital · US

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
VASCULAR, PULMONARY AND RENAL INJURYT32HL007627 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GIMBRONE, MICHAEL A, MITCHELL, RICHARD N · 1985 to 2019
$12.7M
LYMPHOCYTE SIGNALING DEFECTS IN PATIENTS WITH LUPUSR01AI042269 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI TSOKOS, GEORGE C · 1998 to 2017
$6.8M
T cells in LupusR01AI148161 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI TSOKOS, GEORGE C · 2020 to 2024
$2.2M
NHLBI NIH HHS T32 HL007627NIAID NIH HHS R01 AI042269NIAID NIH HHS R01 AI148161NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

Drug repurposing has the advantage of identifying potential treatments on a shortened timescale. In response to the pandemic spread of SARS-CoV-2, we took advantage of a high-content screen of 3,713 compounds at different stages of clinical development to identify FDA-approved compounds that reduce mucin-1 (MUC1) protein abundance. Elevated MUC1 levels predict the development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) and correlate with poor clinical outcomes. Our screen identifies fostamatinib (R788), an inhibitor of spleen tyrosine kinase (SYK) approved for the treatment of chronic immune thrombocytopenia, as a repurposing candidate for the treatment of ALI.

Indexed as

acute lung injuryacute respiratory distress syndromeALIARDSCOVID-19drug repurposingfostamatinibMUC1SARS-CoV-2

Identifiers

PMID33294858
PMCPMC7691435
OpenAlexW3095912752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.